![iShares 20 plus Year Treasury Bond BuyWrite Strategy ETF](/common/images/company/A_TLTW.png)
iShares 20 plus Year Treasury Bond BuyWrite Strategy ETF (TLTW)
AMEX
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations...
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -0.0757002271007 | 26.42 | 26.56 | 26.2 | 946300 | 26.47979641 | SP |
4 | 0.41 | 1.57752981916 | 25.99 | 26.56 | 25.5123 | 644784 | 26.15783124 | SP |
12 | 0.73 | 2.84378652123 | 25.67 | 26.56 | 24.8811 | 474942 | 25.88884238 | SP |
26 | -0.13 | -0.490011307953 | 26.53 | 26.77 | 24.75 | 458370 | 25.94891577 | SP |
52 | -4.91 | -15.6818907697 | 31.31 | 31.4701 | 24.75 | 545165 | 27.24020634 | SP |
156 | -13.21 | -33.3501641 | 39.61 | 39.94 | 24.75 | 378134 | 28.71711715 | SP |
260 | -13.21 | -33.3501641 | 39.61 | 39.94 | 24.75 | 378134 | 28.71711715 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.